Study on risk-sharing agreements in South Korea and its implication for medical insurance admission in China
ZHANG Tian-qi
ZENG Liu-chun
ZHANG Wen
WANG Lin-ning
LU Yun
Abstract：China's innovative drug development is now in a phase of rapid ascendance.Within this dynamic ecosystem,risk-sharing agreement have emerged as a pivotal policy instrument that enables multi-stakeholder collaboration-governments,commercial payers,and biopharmaceutical companies——to jointly tackle the multifaceted challenges posed by clinical efficacy uncertainties,exorbitant R&D costs,and reimbursement pressures inherent in novel drug development.This study conducted a comprehensive analysis of South Korea's pharmaceutical risk-sharing agreement policy through five key dimensions:scope of application,typological classification,refund guarantee mechanisms,operational procedures,and implementation effectiveness.Based on the research findings,the following recommendations were proposed:exploring the scope of application starting with special drugs,developing diversified typologies of risk-sharing agreements,and implementing safeguards for the risk-sharing agreement process.These policy recommendations seek to further refine China's innovative drug policies.
Keywords：risk-sharing agreementinnovative drugSouth Korea
Publication Date：2026-01-30
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：7( 121-127 )